New natural protein tyrosine phosphatase 1B inhibitors from Gynostemma pentaphyllum.

IF 5.6 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY
Xianting Wang, Yidan Deng, Jianmei Wang, Lin Qin, Yimei Du, Qianru Zhang, Di Wu, Xingdong Wu, Jian Xie, Yuqi He, Daopeng Tan
{"title":"New natural protein tyrosine phosphatase 1B inhibitors from <i>Gynostemma pentaphyllum</i>.","authors":"Xianting Wang, Yidan Deng, Jianmei Wang, Lin Qin, Yimei Du, Qianru Zhang, Di Wu, Xingdong Wu, Jian Xie, Yuqi He, Daopeng Tan","doi":"10.1080/14756366.2024.2360063","DOIUrl":null,"url":null,"abstract":"<p><p>Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease mainly caused by insulin resistance, which can lead to a series of complications such as cardiovascular disease, retinopathy, and its typical clinical symptom is hyperglycaemia. Glucosidase inhibitors, including Acarbose, Miglitol, are commonly used in the clinical treatment of hypoglycaemia. In addition, Protein tyrosine phosphatase 1B (PTP1B) is also an important promising target for the treatment of T2DM. <i>Gynostemma pentaphyllum</i> is a well-known oriental traditional medicinal herbal plant, and has many beneficial effects on glucose and lipid metabolism. In the present study, three new and nine known dammarane triterpenoids isolated from <i>G. pentaphyllum</i>, and their structures were elucidated by spectroscopic methods including HR-ESI-MS,<sup>1</sup>H and <sup>13</sup>C NMR and X-ray crystallography. All these compounds were evaluated for inhibitory activity against α-glucosidase, α-amylase and PTP1B. The results suggested that compounds <b>7</b>∼<b>10</b> were potential antidiabetic agents with significantly inhibition activity against PTP1B in a dose-dependent manner.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":5.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182071/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Enzyme Inhibition and Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14756366.2024.2360063","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease mainly caused by insulin resistance, which can lead to a series of complications such as cardiovascular disease, retinopathy, and its typical clinical symptom is hyperglycaemia. Glucosidase inhibitors, including Acarbose, Miglitol, are commonly used in the clinical treatment of hypoglycaemia. In addition, Protein tyrosine phosphatase 1B (PTP1B) is also an important promising target for the treatment of T2DM. Gynostemma pentaphyllum is a well-known oriental traditional medicinal herbal plant, and has many beneficial effects on glucose and lipid metabolism. In the present study, three new and nine known dammarane triterpenoids isolated from G. pentaphyllum, and their structures were elucidated by spectroscopic methods including HR-ESI-MS,1H and 13C NMR and X-ray crystallography. All these compounds were evaluated for inhibitory activity against α-glucosidase, α-amylase and PTP1B. The results suggested that compounds 710 were potential antidiabetic agents with significantly inhibition activity against PTP1B in a dose-dependent manner.

从绞股蓝中提取的新型天然蛋白酪氨酸磷酸酶 1B 抑制剂。
2 型糖尿病(T2DM)是一种以胰岛素抵抗为主要病因的慢性代谢性疾病,可引发心血管疾病、视网膜病变等一系列并发症,其典型临床症状为高血糖。阿卡波糖、米格列醇等糖苷酶抑制剂是临床治疗低血糖的常用药物。此外,蛋白酪氨酸磷酸酶 1B(PTP1B)也是治疗 T2DM 的一个重要靶点。绞股蓝是一种著名的东方传统药用植物,对糖、脂代谢有许多有益的作用。本研究从绞股蓝中分离出了三种新的和九种已知的达玛烷三萜类化合物,并通过 HR-ESI-MS 、1H 和 13C NMR 以及 X 射线晶体学等光谱方法阐明了它们的结构。评估了所有这些化合物对 α-葡萄糖苷酶、α-淀粉酶和 PTP1B 的抑制活性。结果表明,化合物 7∼10 是潜在的抗糖尿病药物,其对 PTP1B 的抑制活性呈剂量依赖性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
10.30
自引率
10.70%
发文量
195
审稿时长
4-8 weeks
期刊介绍: Journal of Enzyme Inhibition and Medicinal Chemistry publishes open access research on enzyme inhibitors, inhibitory processes, and agonist/antagonist receptor interactions in the development of medicinal and anti-cancer agents. Journal of Enzyme Inhibition and Medicinal Chemistry aims to provide an international and interdisciplinary platform for the latest findings in enzyme inhibition research. The journal’s focus includes current developments in: Enzymology; Cell biology; Chemical biology; Microbiology; Physiology; Pharmacology leading to drug design; Molecular recognition processes; Distribution and metabolism of biologically active compounds.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信